Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Camp4 Therapeutics (CAMP) Common Equity: 2023-2025

Historic Common Equity for Camp4 Therapeutics (CAMP) over the last 1 years, with Sep 2025 value amounting to $58.7 million.

  • Camp4 Therapeutics' Common Equity rose 136.90% to $58.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.7 million, marking a year-over-year increase of 136.90%. This contributed to the annual value of $63.1 million for FY2024, which is 151.03% up from last year.
  • Camp4 Therapeutics' Common Equity amounted to $58.7 million in Q3 2025, which was up 46.72% from $40.0 million recorded in Q2 2025.
  • Over the past 5 years, Camp4 Therapeutics' Common Equity peaked at $63.1 million during Q4 2024, and registered a low of -$159.0 million during Q3 2024.
  • Its 3-year average for Common Equity is -$25.8 million, with a median of $40.0 million in 2025.
  • Over the last 5 years, Camp4 Therapeutics' Common Equity had its largest YoY gain of 151.03% in 2024, and its largest YoY loss of 42.51% in 2024.
  • Quarterly analysis of 3 years shows Camp4 Therapeutics' Common Equity stood at -$123.7 million in 2023, then skyrocketed by 151.03% to $63.1 million in 2024, then soared by 136.90% to $58.7 million in 2025.
  • Its Common Equity stands at $58.7 million for Q3 2025, versus $40.0 million for Q2 2025 and $51.6 million for Q1 2025.